BIOCRYST PHARMACEUTICALS, INC.

BioCryst Pharmaceuticals announces HSE Ireland's recommendation of ORLADEYO® (berotralstat) for routine prevention of hereditary angioedema (HAE) in patients 12 years and older, providing the first oral, once-daily therapy for HAE in Ireland.

The red biotechnology market is projected to grow from $509.71 billion in 2023 to $867.20 billion by 2028, driven by advancements in personalized medicine, biosimilars, and genetic engineering. Major players include Pfizer, Roche, Bayer, and Amgen.

Iptacopan (Fabhalta) showed a clinically meaningful reduction in proteinuria and confirmed clinical benefit of alternative pathway inhibition in IgA nephropathy, with a 38.3% lower UPCR than placebo by month 9. The study also found significant decreases in complement pathway biomarkers, supporting selective alternative pathway inhibition.

BioCryst Pharmaceuticals, Inc. to report Q3 2024 financial results on Nov 4, 2024, with a conference call at 8:30 a.m. ET. BioCryst is a global biotech focused on rare diseases, commercializing ORLADEYO® and advancing a pipeline of therapies.